Company intelligence / Profile preview
Gelteq
Melbourne, Victoria, Australiagelteq.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has completed preclinical studies with multiple active pharmaceutical ingredients (APIs) using its patented gel technology. Clinical trials are planned but have not yet commenced as of mid–2024. The technology addresses key challenges in oral drug administration such as dysphagia and dosage control.
- Therapeutic areas
- EndocrinologyImmunologyOtherGastroenterologyCardiovascularNeurology
- Modalities
- Oral ingestible gels for drug and nutrient delivery (enables delivery of small molecules, macro/micronutrients, water/lipid-soluble compounds)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Gelteq.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gelteq.